Pratyush Giri

1.8k total citations · 1 hit paper
29 papers, 451 citations indexed

About

Pratyush Giri is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Pratyush Giri has authored 29 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pathology and Forensic Medicine, 14 papers in Oncology and 12 papers in Genetics. Recurrent topics in Pratyush Giri's work include Lymphoma Diagnosis and Treatment (19 papers), Chronic Lymphocytic Leukemia Research (11 papers) and CAR-T cell therapy research (10 papers). Pratyush Giri is often cited by papers focused on Lymphoma Diagnosis and Treatment (19 papers), Chronic Lymphocytic Leukemia Research (11 papers) and CAR-T cell therapy research (10 papers). Pratyush Giri collaborates with scholars based in Australia, United States and Germany. Pratyush Giri's co-authors include Nancy L. Bartlett, Elicia Penuel, Matthew J. Matasar, Michael C. Wei, Lihua E. Budde, Matthew Ku, Sarit Assouline, Stephen J. Schuster, Chan Y. Cheah and Huang Huang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Pratyush Giri

23 papers receiving 442 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Pratyush Giri

Since Specialization

Citations

This map shows the geographic impact of Pratyush Giri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pratyush Giri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pratyush Giri more than expected).

Fields of papers citing papers by Pratyush Giri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pratyush Giri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pratyush Giri. The network helps show where Pratyush Giri may publish in the future.

Co-authorship network of co-authors of Pratyush Giri

This figure shows the co-authorship network connecting the top 25 collaborators of Pratyush Giri. A scholar is included among the top collaborators of Pratyush Giri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pratyush Giri. Pratyush Giri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study 2025 ·BMC Cancer ·(unknown), Samuel P. Costello, Robert V. Bryant, Sarah Haylock‐Jacobs, Craig Haifer, Cindy H. Lee, David T Yeung, Pratyush Giri, (unknown), Joanne M. Bowen, Feargal J. Ryan, (unknown), Hannah R. Wardill	0
2	Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II 2024 ·Blood ·Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung Soo Yoon, Keith Fay, Georg Heß, Martin Dreyling, Norma C. Gutiérrez, (unknown), Antonia Kwan, Elicia Penuel, Samuel Tracy, (unknown), (unknown), Volker Wiebking, Michael C. Wei, Lihua E. Budde	4
3	IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, (unknown), Keith Fay, Loretta J. Nastoupil, Michael C. Wei, (unknown), Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde	0
4	Australasian Leukaemia & Lymphoma Group NHL32 Block PCNSL: An Open Label Phase II Study of Pembrolizumab Following Chemoimmunotherapy for Newly Diagnosed Primary Central Nervous System Lymphoma - Trial in Progress 2024 ·Blood ·(unknown), Colm Keane, Christina Brown, Pratyush Giri, Gavin Cull, Masa Lasica, (unknown), Joel Wight, Marjan Tabesh, Belinda Butcher, (unknown), Eliza A. Hawkes, Gareth P. Gregory	0
5	Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era 2024 ·Internal Medicine Journal ·(unknown), (unknown), Cameron Wellard, (unknown), (unknown), Geoffrey Chong, Tara Cochrane, Gavin Cull, Pratyush Giri, Nada Hamad, Anna Johnston, Denise Lee, (unknown), Susan Morgan, Stephen P. Mulligan, Dipti Talaulikar, (unknown), Erica M. Wood, Eliza A. Hawkes, Stephen Opat	0
6	Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma 2024 ·Blood ·Katharine L. Lewis, Pratyush Giri, (unknown), Piers Blombery, Colm Keane, (unknown), Tara Cochrane, (unknown), (unknown), (unknown), Roslyn J. Francis, Mannu Walia, Julia M. Carlson, Belinda Butcher, Chan Y. Cheah	0
7	Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study 2024 ·Blood ·Mazyar Shadman, Nancy L. Bartlett, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Laurie H. Sehn, John Kuruvilla, Pratyush Giri, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, (unknown), (unknown), Samuel Tracy, Antonia Kwan, Elicia Penuel, Lihua E. Budde	1
8	Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study 2023 ·Blood ·Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, Shen Yin, Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde	14
9	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study breakdown → 2022 ·The Lancet Oncology ·Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Chan Y. Cheah, Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L. Bartlett	244
10	Krankheitslast von Lungenkrebs in Deutschland: Epidemiologie und Kosten 2022 ·Forum ·Diego Hernández, Pratyush Giri, (unknown), Michael Schlander	1
11	Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study 2022 ·Blood ·Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, (unknown), Keith Fay, Matthew Ku, Loretta J. Nastoupil, Michael C. Wei, (unknown), Iris To, Huang Huang, (unknown), Elicia Penuel, Lihua E. Budde	21
12	Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry 2022 ·Leukemia & lymphoma ·(unknown), Cameron Wellard, (unknown), Dipti Talaulikar, Colm Keane, Stephen Opat, Pratyush Giri, Adrian Minson, Chan Y. Cheah, (unknown), Denise Lee, Geoffrey Chong, Anna Johnston, Tara Cochrane, (unknown), Nada Hamad, Erica M. Wood, Eliza A. Hawkes	1
13	Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts 2020 ·Blood ·Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, Sarit Assouline, Nancy L. Bartlett, Matthew Ku, Pratyush Giri, Anna Johnston, Ian W. Flinn, André Goy, Dimitrios Tzachanis, Carol O’Hear, Shen Yin, Iris To, (unknown), Chi‐Chung Li, Brendan C. Bender, Elicia Penuel, Huang Huang, Lihua E. Budde	27
14	Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab 2020 ·Respirology Case Reports ·(unknown), Pratyush Giri, Caroline Smith, Phan Nguyen, Paul N. Reynolds	1
15	The utility of CD200 expression and modified Matutes score in the diagnostic differentiation of mantle cell lymphoma and chronic lymphocytic leukemia using flow cytometry 2019 ·Leukemia & lymphoma ·Nicholas Myles, Pratyush Giri, (unknown), (unknown)	6
16	An Observational Study of the Prescribing Practices and Patient Reported Outcomes Measures in Older People with Myelodysplastic Syndrome 2019 ·Blood ·(unknown), Michelle Wall, Rakchha Chhetri, (unknown), Deepak Singhal, Pratyush Giri, Timothy To, Devendra Hiwase	1
17	Geriatric Assessment in Older People with Myelodysplasia Is Predictive of Azacitidine Therapy Completion and Survival: A Prospective Interventional Study at the Royal Adelaide Hospital 2018 ·Blood ·(unknown), Michelle Wall, Rakchha Chhetri, (unknown), Deepak Singhal, Nimit Singhal, David M. Ross, Luen Bik To, Peter Bardy, Pratyush Giri, Gillian E. Caughey, Sepehr Shakib, Timothy To, Devendra Hiwase	2
18	Duplication on Chromosome 14q Identified in Familial Predisposition to Myeloid Malignancies and Myeloproliferative Neoplasms 2017 ·Blood ·Christopher N Hahn, (unknown), Milena Babic, Jinghua Feng, Paul Wang, Monika Kutyna, Sarah Moore, Anna Brown, Richard J. D’Andrea, Deepak Singhal, Andreas Schreiber, Pratyush Giri, David M. Ross, Devendra Hiwase, Hamish S. Scott	3
19	Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study 2017 ·The Lancet Haematology ·Wojciech Jurczak, (unknown), (unknown), (unknown), (unknown), Pratyush Giri, Nelson Castro, Juliana Pereira, Luiza Akria, (unknown), (unknown), Peijuan Zhu, (unknown), Angela Zubel, (unknown), (unknown)	62
20	Thoracic Outlet Syndrome Following Breast Implant Rupture 2015 ·Plastic & Reconstructive Surgery Global Open ·(unknown), Yugesh Caplash, Pratyush Giri, Daniel Kearney, Marcus Wagstaff	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact